Published in BMC Med on December 23, 2005
Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study. BMC Psychiatry (2011) 1.48
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry (2006) 1.19
Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res (2011) 1.16
Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry (2013) 1.12
Predicting the brain response to treatment using a Bayesian hierarchical model with application to a study of schizophrenia. Hum Brain Mapp (2008) 1.05
Predictors of switching antipsychotic medications in the treatment of schizophrenia. BMC Psychiatry (2010) 0.98
Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc (2009) 0.93
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psychiatry (2009) 0.93
The promise and reality of pharmacogenetics in psychiatry. Psychiatr Clin North Am (2010) 0.92
Predictors of premature discontinuation of treatment in multiple disease states. Patient Prefer Adherence (2009) 0.90
The heterogeneity of antipsychotic response in the treatment of schizophrenia. Psychol Med (2010) 0.87
Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example. Cost Eff Resour Alloc (2009) 0.87
Patient perspectives on antipsychotic treatments and their association with clinical outcomes. Patient Prefer Adherence (2010) 0.87
Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia. Patient Prefer Adherence (2007) 0.87
Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence. Patient Prefer Adherence (2011) 0.86
Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties. Patient Prefer Adherence (2012) 0.85
Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics. BMC Psychiatry (2011) 0.85
Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophrenia. Patient Prefer Adherence (2010) 0.81
Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians. Patient Prefer Adherence (2011) 0.81
Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER. Patient Prefer Adherence (2008) 0.79
Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder. Ther Clin Risk Manag (2008) 0.79
Antipsychotic agents: efficacy and safety in schizophrenia. Drug Healthc Patient Saf (2012) 0.79
The effect of race-ethnicity on the comparative effectiveness of clozapine among Medicaid beneficiaries. Psychiatr Serv (2013) 0.78
Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics. J Child Adolesc Psychopharmacol (2013) 0.78
Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study. Psychopharmacology (Berl) (2016) 0.78
Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia. BMC Psychiatry (2011) 0.77
Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database. BMC Psychiatry (2012) 0.77
Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. Clinicoecon Outcomes Res (2013) 0.77
Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice. Br J Clin Pharmacol (2014) 0.76
Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan. Patient Prefer Adherence (2011) 0.76
Towards a framework for treatment effectiveness in schizophrenia. Neuropsychiatr Dis Treat (2014) 0.75
Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria. Ther Adv Psychopharmacol (2017) 0.75
One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study. Pragmat Obs Res (2012) 0.75
Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials. BMC Psychiatry (2009) 0.75
Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation. Patient Prefer Adherence (2012) 0.75
Risperidone long-acting injection in the treatment of schizophrenia spectrum illnesses: A retrospective chart review of 19 patients in the Vancouver Community Mental Health Organization (Vancouver, Canada). Curr Ther Res Clin Exp (2007) 0.75
Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. Eur Child Adolesc Psychiatry (2015) 0.75
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med (2005) 28.99
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry (1988) 12.39
Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care (1975) 5.81
Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry (2002) 5.25
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol (1997) 3.62
Compliance with medication regimens for mental and physical disorders. Psychiatr Serv (1998) 3.35
Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry (2003) 3.18
Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull (1997) 2.90
Neuroleptics and the natural course of schizophrenia. Schizophr Bull (1991) 2.31
Management of treatment resistance in schizophrenia. Biol Psychiatry (2001) 2.20
Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry (2003) 2.11
Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry (2002) 1.76
How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychol Med (2003) 1.54
Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res (1997) 1.52
Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry (2004) 1.46
An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv (2003) 1.43
Adherence to antipsychotic medications. J Clin Psychiatry (1999) 1.38
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry (2005) 1.16
Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl) (2001) 1.13
Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull (1993) 1.05
Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J Clin Psychiatry (1999) 0.90
Dropout rates with olanzapine or risperidone: a multi-centre observational study. Eur J Clin Pharmacol (2003) 0.85
Neuroleptic treatment and prediction of response. Psychopharmacol Bull (1988) 0.83
Patients' opinions concerning side effects of depot neuroleptics. Am J Psychiatry (1992) 0.81
Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science (2006) 5.31
Aortic valve surgery after previous coronary artery bypass grafting with functioning internal mammary artery grafts. Ann Thorac Surg (2002) 2.88
Results and predictors of early and late outcomes of coronary artery bypass graft surgery in octogenarians. J Cardiothorac Vasc Anesth (2007) 2.73
Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology (2008) 2.43
EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography. J Am Soc Echocardiogr (2012) 2.41
Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology (2010) 2.37
Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med (2007) 2.32
A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry (2006) 2.28
Integrated thoracic residency program applicants: the best and the brightest? Ann Thorac Surg (2011) 2.22
Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. Proc Natl Acad Sci U S A (2010) 2.19
Bilateral internal mammary artery grafts, mortality and morbidity: an analysis of 1 526 360 coronary bypass operations. Heart (2013) 2.15
The role of hemochromatosis susceptibility gene mutations in protecting against iron deficiency in celiac disease. Gastroenterology (2002) 2.12
Management of systolic anterior motion after mitral valve repair: an algorithm. J Thorac Cardiovasc Surg (2012) 2.07
Guidelines for reporting mortality and morbidity after cardiac valve interventions. Ann Thorac Surg (2008) 2.04
Cardiac myxoma: preoperative diagnosis using a multimodal imaging approach and surgical outcome in a large contemporary series. Interact Cardiovasc Thorac Surg (2007) 2.03
Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health (2006) 1.97
CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. J Hepatol (2012) 1.95
Human MAIT and CD8αα cells develop from a pool of type-17 precommitted CD8+ T cells. Blood (2011) 1.83
Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology (2010) 1.82
Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome. Circulation (2009) 1.78
A propensity score-adjusted retrospective comparison of early and mid-term results of mitral valve repair versus replacement in octogenarians. Eur Heart J (2010) 1.78
Guidelines for reporting mortality and morbidity after cardiac valve interventions. J Thorac Cardiovasc Surg (2008) 1.76
A three-dimensional ring annuloplasty for the treatment of tricuspid regurgitation. Ann Thorac Surg (2006) 1.75
Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol (2003) 1.70
The intraoperative "ink test": a novel assessment tool in mitral valve repair. J Thorac Cardiovasc Surg (2007) 1.64
Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol (2010) 1.61
Incidence, topography, predictors and long-term survival after stroke in patients undergoing coronary artery bypass grafting. Ann Thorac Surg (2008) 1.60
Primary sclerosing cholangitis. Lancet (2013) 1.59
Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells. J Immunol (2002) 1.55
Inverted left atrial appendage. J Am Coll Cardiol (2009) 1.55
Predictors and early and late outcomes of dialysis-dependent patients in contemporary cardiac surgery. J Cardiothorac Vasc Anesth (2008) 1.54
Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry (2009) 1.53
CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J Immunol (2005) 1.49
Recruitment of lymphocytes to the human liver. Immunol Cell Biol (2002) 1.49
Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication. Hepatology (2013) 1.47
Tracheostomy is not a risk factor for deep sternal wound infection after cardiac surgery. Ann Thorac Surg (2007) 1.46
A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology (2009) 1.46
Chemokines in the immunopathogenesis of hepatitis C infection. Hepatology (2009) 1.46
Predictors and outcomes of seizures after cardiac surgery: a multivariable analysis of 2,578 patients. Ann Thorac Surg (2011) 1.45
Liberal use of delayed sternal closure for postcardiotomy hemodynamic instability. Ann Thorac Surg (2002) 1.45
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation, Right Ventricular Function, and Pulmonary Artery Hypertension After Repair of Mitral Valve Prolapse. J Am Coll Cardiol (2015) 1.43
Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med (2004) 1.43
Excellent outcomes with use of synthetic vascular grafts for treatment of mycotic aortic pseudoaneurysms after heart transplantation. Ann Thorac Surg (2011) 1.42
[Remodeling annuloplasty using a prosthetic ring designed for correcting type-IIIb ischemic mitral regurgitation]. Rev Esp Cardiol (2007) 1.41
Does prior coronary bypass surgery present a unique risk for reoperative valve surgery? Ann Thorac Surg (2013) 1.41
Epithelial inflammation is associated with CCL28 production and the recruitment of regulatory T cells expressing CCR10. J Immunol (2006) 1.40
Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: pooled results from 10 phase 1 studies. J Clin Psychopharmacol (2012) 1.40
Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver. Gastroenterology (2008) 1.39
Epidemiology of deep sternal wound infection in cardiac surgery. J Cardiothorac Vasc Anesth (2009) 1.38
LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus. Virology (2005) 1.37
Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull (2007) 1.36
Predictors and outcome of gastrointestinal complications in patients undergoing cardiac surgery. Ann Surg (2007) 1.35
Isolation of primary human hepatocytes from normal and diseased liver tissue: a one hundred liver experience. PLoS One (2011) 1.34
EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography. Eur Heart J Cardiovasc Imaging (2012) 1.33
Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med (2012) 1.32
Long-term outcomes of tricuspid valve replacement in the current era. Ann Thorac Surg (2005) 1.31
Gene expression profiling in postmortem prefrontal cortex of major depressive disorder. J Neurosci (2007) 1.30
CXCR 3 activation promotes lymphocyte transendothelial migration across human hepatic endothelium under fluid flow. Am J Pathol (2005) 1.30
Gut homing receptors on CD8 T cells are retinoic acid dependent and not maintained by liver dendritic or stellate cells. Gastroenterology (2009) 1.29
Guidelines for reporting mortality and morbidity after cardiac valve interventions. Eur J Cardiothorac Surg (2008) 1.26
Mitral valve repair with Carpentier-McCarthy-Adams IMR ETlogix annuloplasty ring for ischemic mitral regurgitation: early echocardiographic results from a multi-center study. Circulation (2006) 1.24
Immune interactions in hepatic fibrosis. Clin Liver Dis (2008) 1.23
Reactive oxygen species mediate human hepatocyte injury during hypoxia/reoxygenation. Liver Transpl (2010) 1.23
Association of T-zone reticular networks and conduits with ectopic lymphoid tissues in mice and humans. Am J Pathol (2011) 1.21
Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med (2014) 1.20
Hepatic expression of secondary lymphoid chemokine (CCL21) promotes the development of portal-associated lymphoid tissue in chronic inflammatory liver disease. Am J Pathol (2002) 1.19
A near 100% repair rate for mitral valve prolapse is achievable in a reference center: implications for future guidelines. J Thorac Cardiovasc Surg (2012) 1.18
The role of cytokines and chemokines in the development of steatohepatitis. Semin Liver Dis (2007) 1.18
Seeking a higher standard for degenerative mitral valve repair: begin with etiology. J Thorac Cardiovasc Surg (2008) 1.16
The role of chemokines in the recruitment of lymphocytes to the liver. J Autoimmun (2009) 1.14
Etiologic classification of degenerative mitral valve disease: Barlow's disease and fibroelastic deficiency. Semin Thorac Cardiovasc Surg (2007) 1.13
Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet (2002) 1.13
Liberal use of tricuspid-valve annuloplasty during left-ventricular assist device implantation. Eur J Cardiothorac Surg (2012) 1.13
Common lymphatic endothelial and vascular endothelial receptor-1 mediates the transmigration of regulatory T cells across human hepatic sinusoidal endothelium. J Immunol (2011) 1.13
The composition of intrahepatic lymphocytes: shaped by selective recruitment? Trends Immunol (2004) 1.12
Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics. Hepatology (2012) 1.12
Aortic valve and ascending aorta guidelines for management and quality measures. Ann Thorac Surg (2013) 1.11
T lymphocyte recruitment into renal cell carcinoma tissue: a role for chemokine receptors CXCR3, CXCR6, CCR5, and CCR6. Eur Urol (2011) 1.10
Results and predictors of early and late outcome of coronary artery bypass grafting in patients with severely depressed left ventricular function. Ann Thorac Surg (2007) 1.09
Interleukin-10 secretion differentiates dendritic cells from human liver and skin. Am J Pathol (2004) 1.08
Management of mild to moderate aortic stenosis at the time of coronary artery bypass grafting. J Heart Valve Dis (2002) 1.08
Autophagy: a cyto-protective mechanism which prevents primary human hepatocyte apoptosis during oxidative stress. Autophagy (2012) 1.08
Early and late outcome of cardiac surgery in patients with liver cirrhosis. Liver Transpl (2007) 1.08
Role for hedgehog pathway in regulating growth and function of invariant NKT cells. Eur J Immunol (2009) 1.07
A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol (2006) 1.06
Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells. Hepatology (2014) 1.06
Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol (2009) 1.05
CX(3)CR1 and vascular adhesion protein-1-dependent recruitment of CD16(+) monocytes across human liver sinusoidal endothelium. Hepatology (2010) 1.05
Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol (2008) 1.05
Predictors and early and late outcomes of respiratory failure in contemporary cardiac surgery. Chest (2008) 1.05
Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Blood (2008) 1.05
Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. Hepatol Int (2010) 1.05
Expression of DC-SIGN and DC-SIGNR on human sinusoidal endothelium: a role for capturing hepatitis C virus particles. Am J Pathol (2006) 1.04
Mitral valve hemodynamics after repair of acute posterior leaflet prolapse: quadrangular resection versus triangular resection versus neochordoplasty. J Thorac Cardiovasc Surg (2009) 1.04
Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr Res (2013) 1.04
The role of chemokines in the recruitment of lymphocytes to the liver. Dig Dis (2010) 1.04
Interactions of LSECtin and DC-SIGN/DC-SIGNR with viral ligands: Differential pH dependence, internalization and virion binding. Virology (2008) 1.04
GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs (2010) 1.03
Incidence, imaging analysis, and early and late outcomes of stroke after cardiac valve operation. Am J Cardiol (2008) 1.03